BMJ Oncology,
Год журнала:
2023,
Номер
2(1), С. e000090 - e000090
Опубликована: Окт. 1, 2023
Advances
in
the
detection
and
treatment
of
cancer
have
translated
into
improved
survival
rates
a
growing
population
survivors.
These
include
those
living
with
individuals
free
disease
following
treatment.
Epidemiological
studies
demonstrate
that
survivors
are
at
an
increased
risk
cardiovascular
(CVD),
(CV)
mortality
overtaking
some
tumour
types.
Cancer
CVD
share
common
aetiological
factors,
for
example,
age,
tobacco
use
obesity,
as
well
shared
inflammatory
pathogenesis.
The
CV
risks
mediastinal
radiotherapy
chemotherapy,
first
observed
1970s
anthracyclines,
long
been
appreciated.
More
recently,
targeted
anticancer
therapeutics
(human
epidermal
growth
factor
receptor-2
therpies,
vascular
endothelial
inhibitors,
second/third-generation
BCR-ABL
multiple
myeloma
therapies
combination
RAF
MEK
inhibitors
particular)
immunotherapies
added
to
burden
treatment-related
toxicity.
Additionally,
therapy
may
indirectly
impact
on
health
by
decreasing
physical
activity,
increasing
weight
gain
accelerating
ageing
process.
Improving
overall
outcomes
considering
cardiological
prevention
management
survivorship
is
area
interest.
assessment
recommended
post-cancer
accordance
primary
guidelines.
European
Society
Cardiology
2022
guidelines
also
recommend
enhanced
surveillance
after
treatments
moderate
high
consequences.
aim
this
article
provide
overview
interconnections
between
CVD,
review
current
recommendations,
highlight
key
areas
ongoing
future
research.
Journal of Cardiovascular Development and Disease,
Год журнала:
2024,
Номер
11(9), С. 263 - 263
Опубликована: Авг. 27, 2024
Cancer
and
heart
failure
(HF)
are
increasingly
relevant
worldwide,
both
from
an
epidemiologic
clinical
point
of
view.
This
review
aims
to
explore
the
relationship
between
cancer
HF
by
underscoring
risk
factors
disclosing
cardiotoxic
effects
current
chemotherapy
agents.
We
also
deal
with
evidence
on
diagnosis
management
related
therapy.
Finally,
we
will
address
main
gaps
in
knowledge
future
perspectives
this
field.
G3 Genes Genomes Genetics,
Год журнала:
2023,
Номер
13(5)
Опубликована: Март 6, 2023
Abstract
Received
on
16
January
2023;
accepted
21
February
2023Kinases
are
key
regulators
of
cellular
signal
transduction
pathways.
Many
diseases,
including
cancer,
associated
with
global
alterations
in
protein
phosphorylation
networks.
As
a
result,
kinases
frequent
targets
drug
discovery
efforts.
However,
target
identification
and
assessment,
critical
step
targeted
that
involves
identifying
essential
genetic
mediators
disease
phenotypes,
can
be
challenging
complex,
heterogeneous
diseases
like
where
multiple
concurrent
genomic
common.
Drosophila
is
particularly
useful
model
system
to
identify
novel
biological
processes
through
unbiased
screens.
Here,
we
report
2
classic
modifier
screens
focusing
the
kinome
kinase
different
backgrounds:
KRAS
TP53
PTEN
APC,
multigenic
cancer
4
genes
recurrently
mutated
human
colon
tumors
alone,
simpler
one
most
frequently
altered
pathways
cancer.
These
identified
hits
unique
each
shared
by
both,
emphasizing
importance
capturing
complexity
tumor
genome
landscapes
experimental
models.
Our
follow-up
analysis
from
KRAS-only
screen
suggests
classical
heterozygous
mutant
backgrounds
result
modest,
nonlethal
reduction
candidate
gene
activity
context
whole
animal—a
goal
systemic
treatment—may
approach
rate-limiting
vulnerabilities
models
as
ideal
targets.
Cancers,
Год журнала:
2023,
Номер
15(11), С. 3055 - 3055
Опубликована: Июнь 5, 2023
It
is
more
likely
that
a
long-term
survivor
will
have
both
cardiovascular
disease
and
cancer
on
account
of
the
progress
in
therapy.
Cardiotoxicity
well-recognized
highly
concerning
adverse
effect
therapies.
This
side
can
manifest
proportion
patients
may
lead
to
discontinuation
potentially
life-saving
anticancer
treatment
regimens.
Consequently,
this
adversely
affect
patient’s
survival
prognosis.
There
are
various
underlying
mechanisms
by
which
each
affects
system.
Similarly,
incidence
events
varies
with
different
protocols
for
malignant
tumors.
In
future,
comprehensive
risk
assessment
clinical
monitoring
should
be
considered
treatments.
Baseline
evaluation
emphasized
prior
initiating
therapy
patients.
Additionally,
we
highlight
there
need
cardio-oncology
avoid
or
prevent
effects.
Cardio-oncology
service
based
identifying
cardiotoxicity,
developing
strategies
reduce
these
toxicities,
minimizing
cardiotoxic
BMJ Oncology,
Год журнала:
2023,
Номер
2(1), С. e000090 - e000090
Опубликована: Окт. 1, 2023
Advances
in
the
detection
and
treatment
of
cancer
have
translated
into
improved
survival
rates
a
growing
population
survivors.
These
include
those
living
with
individuals
free
disease
following
treatment.
Epidemiological
studies
demonstrate
that
survivors
are
at
an
increased
risk
cardiovascular
(CVD),
(CV)
mortality
overtaking
some
tumour
types.
Cancer
CVD
share
common
aetiological
factors,
for
example,
age,
tobacco
use
obesity,
as
well
shared
inflammatory
pathogenesis.
The
CV
risks
mediastinal
radiotherapy
chemotherapy,
first
observed
1970s
anthracyclines,
long
been
appreciated.
More
recently,
targeted
anticancer
therapeutics
(human
epidermal
growth
factor
receptor-2
therpies,
vascular
endothelial
inhibitors,
second/third-generation
BCR-ABL
multiple
myeloma
therapies
combination
RAF
MEK
inhibitors
particular)
immunotherapies
added
to
burden
treatment-related
toxicity.
Additionally,
therapy
may
indirectly
impact
on
health
by
decreasing
physical
activity,
increasing
weight
gain
accelerating
ageing
process.
Improving
overall
outcomes
considering
cardiological
prevention
management
survivorship
is
area
interest.
assessment
recommended
post-cancer
accordance
primary
guidelines.
European
Society
Cardiology
2022
guidelines
also
recommend
enhanced
surveillance
after
treatments
moderate
high
consequences.
aim
this
article
provide
overview
interconnections
between
CVD,
review
current
recommendations,
highlight
key
areas
ongoing
future
research.
